Skip to main content
ConductScienceScienceDex
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

231

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

231 results for “Clinical feature”

Learn how ShareScore rates datasets ↗
geo12/100

Large B-Cell Lymphomas in Pediatric and Young Adults Display Clinically Relevant Molecular Features Distinguishable from Adult Counterparts

GEO Series GSE128294. Homo sapiens. 79 samples. Type: Expression profiling by array; SNP genotyping by SNP array; Genome variation profiling by genome tiling array; Genome variation profiling by SNP array.

openGEO-OpenNov 2019View details →
geo12/100

Large B-Cell Lymphomas in Pediatric and Young Adults Display Clinically Relevant Molecular Features Distinguishable from Adult Counterparts [SNP]

GEO Series GSE128292. Homo sapiens. 3 samples. Type: SNP genotyping by SNP array.

openGEO-OpenNov 2019View details →
geo12/100

Large B-Cell Lymphomas in Pediatric and Young Adults Display Clinically Relevant Molecular Features Distinguishable from Adult Counterparts [cytoscan]

GEO Series GSE128214. Homo sapiens. 4 samples. Type: Genome variation profiling by genome tiling array; Genome variation profiling by SNP array.

openGEO-OpenNov 2019View details →
geo12/100

RNA-targeting Cas9 corrects molecular and physiological features in pre-clinical model of myotonic dystrophy type 1

GEO Series GSE152033. Mus musculus. 14 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJul 2020View details →
zenodo12/100

Clinical management and relevance of an alert feature for real-time symptom management in a mobile tool for self-monitoring and self-management of symptoms during anticancer treatment

<p>This dataset reports data from a&nbsp;descriptive study exploring the impact, clinical characteristics and clinical relevance of an alert feature for real-time symptom management in&nbsp; a mobile tool for self-monitoring and self-management of symptoms during anticancer treatment</p>

restrictedSep 2020View details →
zenodo12/100

Dataset related to article "Predictive value of clinical and radiomic features for radiation therapy response in patients with lymph node-positive head and neck cancer"

<p><strong>&nbsp;Abstract</strong></p><p>Background: Prediction of survival and radiation therapy response is challenging in head and neck cancer with metastatic lymph nodes (LNs). Here we developed novel radiomics- and clinical-based predictive models.</p><p>Methods: Volumes of interest of LNs were employed for radiomic features extraction. Radiomic and clinical features were investigated for their predictive value relatively to locoregional failure (LRF), progression-free survival (PFS), and overall survival (OS) and used to build multivariate models.</p><p>Results: Hundred and six subjects were suitable for final analysis. Univariate analysis identified two radiomic features significantly predictive for LRF, and five radiomic features plus two clinical features significantly predictive for both PFS and OS. The area under the curve of receiver operating characteristic curve combining clinical and radiomic predictors for PFS and OS resulted 0.71 (95%CI: 0.60-0.83) and 0.77 (95%CI: 0.64-0.89).</p><p>Conclusions: Radiomic and clinical features resulted to be independent predictive factors, but external independent validation is mandatory to support these findin</p>

restrictedNov 2023View details →
zenodo12/100

Association of clinically evident eye movement abnormalities with motor and cognitive features in patients with motor neuron disorders

<p>Raw data of the article &quot;Association of clinically evident eye movement abnormalities with motor and&nbsp;cognitive features in patients with motor neuron disorders&quot;. The upload includes the anonymized datasets of the discovery and replication ALS cohorts (ALS_DATASET),&nbsp; the control cohort (CTRL_DATASET), and the Alzheimer&#39;s disease cohort (AD_DATASET)&nbsp;and the bedside neurological evaluation checklist&nbsp;(extracts pertaining&nbsp;to oculomotor system and cognitive evaluation). The study was supported by the Italian Ministry of Health (RF-2013-02355764, GR-2016-02364373, and Ricerca Corrente to Istituto Auxologico Italiano, projects ECAS and DAMARE).</p>

restrictedMar 2021View details →
zenodo12/100

Psychogenic Pseudosyncope: Clinical Features, Diagnosis and Management

<p>Psychogenic Pseudosyncope: Clinical Features, Diagnosis and Management</p> <p>Psychogenic Pseudosyncope (PPS) is the appearance of Transient Loss of Consciousness (TLOC) in which movements are absent, but there are no hemodynamic and electroencephalographic modifications as are induced by gravitational challenges which characterize syncope and true loss of consciousness.<br> For younger and adult populations, a detailed history is crucial for the diagnosis. Clinical clues that should raise the suspicion for PPS include prolonged duration of the LOC, eye closure during the episode, unusual triggers, no recognizable prodromes and the high frequency of attacks. The presence of an established diagnosis of syncope should not deter from the concomitant diagnosis of PPS. The gold standard for a proper diagnosis of PPS is the documentation by a tilt test of normal hemodynamic and electroencephalographic parameters, when recorded during an attack.<br> Treatment of PPS, based on the clear and empathetic communication of the diagnosis, can lead to an immediate reduction of attack frequency and lower the need to call on emergency services. Pharmacological treatment of associated psychiatric disorders and psychological interventions may be beneficial in patients with PPS. Cognitive-behavioural therapy holds the most reliable evidence of efficacy.<br> In the present review, we aimed to address PPS with historical aspects, main clinical features and diagnostic tests, current diagnostic classification, underlying neurobiological abnormalities, management and therapy.</p>

restrictedDec 2021View details →
zenodo12/100

dataset related to article "Italian cohort of Lafora disease: Clinical features, disease evolution, and genotype-phenotype correlations"

<p>dataset relateto to article at title</p>

restrictedFeb 2022View details →
zenodo12/100

Hypocalcemia During Lenvatinib Treatment for Advanced Thyroid Cancer: Clinical Features and Management in a Real-Life Setting

<p><strong><em>Background:</em></strong>&nbsp;Several toxicities are recorded during treatment of advanced thyroid cancer (TC) with antiangiogenic drugs, including lenvatinib (LEN). Hypocalcemia was reported in registration studies, but little data are available from real-life cohorts. The aim of our study was to describe the incidence, characteristics, and the management of hypocalcemia in patients on LEN treatment.&nbsp;<strong><em>Methods:</em></strong>&nbsp;This is a retrospective cohort study of consecutive patients with advanced TC, treated with LEN for at least six months at a single tertiary center in Italy. Phosphocalcic metabolism was evaluated during treatment.&nbsp;<strong><em>Results:</em></strong>&nbsp;We included 25 patients treated for a mean of 29 &plusmn; 19 months (range 6-68 months). Hypocalcemia occurred in 6 of the 25 patients (24% [95% confidence interval 9.36-45.13%]), being of grade &ge;3 in 2 of the 25 patients (8%), and recurrent in 4 of 6 patients (67%). The median time to hypocalcemia onset was 3 months (range 0.5-13 months) from starting LEN. No differences were found between patients who developed or not hypocalcemia regarding either starting/mean dose of LEN or clinicopathological characteristics. During the hypocalcemic crisis, the 2 patients with grade &ge;3 hypocalcemia had low magnesium and low or inappropriately normal parathormone (PTH) levels, while 2 of 3 patients with grade 2 hypocalcemia had a secondary hyperparathyroidism. Hypocalcemia was managed with calcium oral supplementation in most cases, although up to 10% of patients required intravenous calcium treatment and transient LEN withdrawal.&nbsp;<strong><em>Conclusions:</em></strong>&nbsp;In this relatively small cohort, we observed an incidence of hypocalcemia of 24%, which is higher than that reported in the registration trial (6.9%). Both PTH-dependent and PTH-independent mechanisms explained hypocalcemia in the present cohort. Monitoring of serum calcium levels is strongly advised during the first year of LEN treatment, as hypocalcemia may be severe. More research is needed to confirm our findings and inform possible risk factors for hypocalcemia in advanced TC patients treated with LEN.</p>

restrictedJan 2023View details →
zenodo8/100

Prevalence and clinical features of armadillo repeat-containing 5 mutations carriers in a single center cohort of patients with bilateral adrenal incidentalomas

<p>Our work provides interesting information both for the finding of a high prevalence of germline armadillo repeat-containing 5 (ARMC5) pathogenic variants in patients with bilateral adrenal incidentalomas and mild autonomous cortisol secretion and, above all, for the novel detection of somatic mutations in the adrenal tissue of patients without germline ARMC5 pathogenic variants. Although the sample size of our cohort is quite small, due to the monocentric nature of the study, a thorough genetic analysis was performed associated with an extensive hormonal, clinical, and comorbidity assessment. We think that these findings can stimulate in the future further studies to elucidate the pathophysiological role of somatic ARMC5 variants in the adrenal tumor development in otherwise wild-type patients and the possible clinical implications.</p>

restrictedAug 2023View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.